Boehringer Ingelheim and Lilly announced that the CAROLINA trial met its primary endpoint, demonstrating no increased cardiovascular (CV) risk with linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.
Type 2 diabetes is associated with significantly increased frailty and fracture risk compared with the general population.
Irrespective of age and weight, women with polycystic ovary syndrome have an increased risk for type 2 diabetes.
For patients with type 2 diabetes and left ventricular hypertrophy, empagliflozin reduced the risk for cardiovascular death vs placebo.
Apnea-hypopnea index during REM sleep is independently associated with diabetic retinopathy in patients with type 2 diabetes.
Poor glycemic control in patients with newly diagnosed type 1 diabetes, but not type 2 diabetes, was associated with an increased risk for low-trauma fracture.
Suppressing albuminuria should be an important target of therapy, according to investigators.
The patient, who had a history of anorexia nervosa-binge purge type, presented to the emergency department with severe abdominal pain, confusion, disorientation, and was experiencing visual hallucinations.
Compared with patients who have onset type 2 diabetes at a usual age, adults with young-onset type 2 diabetes are hospitalized significantly more often in their lifetimes.
Switching from analogue to human insulin is associated with a small increase in hemoglobin A1c (HbA1c) levels.
